Sergey Brin’s nonprofit has received a substantial financial boost of $261 million from the recent MapLight IPO, marking a ...

MapLight Therapeutics Inc. (MPLT) completed its initial public offering of 16,962,500 shares of common stock at $17.00 per share, including the full exercise of underwriters’ op ...

MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating ...

MapLight Therapeutics, Inc. ( ($MPLT) ) has issued an announcement. MapLight Therapeutics, Inc. successfully closed its initial public offering ...

MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced the ...

MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system ...

Zag Bio announced the company’s launch with a $80 million financing round, which includes a recently closed Series A ...

USA-based CNS specialist MapLight Therapeutics successfully made its public debut on Sunday evening, raising more than $250 ...

Incyte axed three prospects to focus on “high-value programs,” its CEO said. Elsewhere, MapLight priced an IPO during the ...

Neuropsychiatric disorder specialist MapLight Therapeutics has made its debut on the Nasdaq, raising $251 million and arriving on the scene valued somewhere north of $800 million.

The health sector faces significant changes as Poland reports an outbreak of bluetongue disease, WOAH confirms. Meanwhile, ...

In a bold move against a backdrop of federal uncertainty, MapLight Therapeutics has gone public, raising $251 million in its ...